Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals. - Wikidata - awgldk - TriplyDB

Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals.

Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals.

http://www.wikidata.org/entity/Q36757051

about

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose Cap analogs modified with 1,2-dithiodiphosphate moiety protect mRNA from decapping and enhance its translational potential.Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In Vivo mRNA Delivery.Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo.Advances in the delivery of RNA therapeutics: from concept to clinical reality.RNA-based therapies for genodermatoses.Modified mRNA as a therapeutic tool to induce cardiac regeneration in ischemic heart disease.Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems.mRNA Cancer Vaccines-Messages that Prevail.Lipid Nanoparticle Systems for Enabling Gene Therapies.mRNA: Fulfilling the Promise of Gene Therapy.mRNA mediates passive vaccination against infectious agents, toxins, and tumors.The European Regulatory Environment of RNA-Based Vaccines.Measuring the Adjuvant Activity of RNA Vaccines.Reprogramming of Pancreatic Exocrine Cells AR42J Into Insulin-producing Cells Using mRNAs for Pdx1, Ngn3, and MafA Transcription Factors.In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy.Human cellular CYBA UTR sequences increase mRNA translation without affecting the half-life of recombinant RNA transcripts.Safety Evaluation of Lipid Nanoparticle-Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey.Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines.Pieter Cullis' quest for a lipid-based, fusogenic delivery system for nucleic acid therapeutics: success with siRNA so what about mRNA?Azido-Functionalized 5' Cap Analogues for the Preparation of Translationally Active mRNAs Suitable for Fluorescent Labeling in Living Cells.mRNA vaccines - a new era in vaccinology.mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma.A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates.New Kids on the Block: RNA-Based Influenza Virus Vaccines.Modulation of mRNA Translation and Cell Viability by Influenza A Virus Derived Nonstructural Protein 1.Label-free analysis of mRNA capping efficiency using RNase H probes and LC-MS.Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses.De Novo Synthesis of Elastin by Exogenous Delivery of Synthetic Modified mRNA into Skin and Elastin-Deficient Cells.Intradermal Delivery of Synthetic mRNA Using Hollow Microneedles for Efficient and Rapid Production of Exogenous Proteins in Skin.Tools for translation: non-viral materials for therapeutic mRNA delivery New Vaccine Technologies to Combat Outbreak Situations Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies

P2860

Q28656365-B045BB7A-3FF3-4D64-A043-9C4819511F1F Q37126611-D8C3139C-1F6C-4B28-AE42-1D5F8A1F0FAD Q37523030-A271BA7E-B642-4CC8-BB96-7D3F926BB6C2 Q37594565-52C05F96-A74B-474A-968A-42F3A551403E Q37607987-48F03028-46D2-40C4-A284-78AFD3752F23 Q38706445-82356BDB-DE2D-4684-85EF-BEBC0A333D1E Q38885425-AD832295-869A-4B79-8876-55204E9F8A48 Q39027005-61F0B71B-0F27-4A28-B74A-CD73F19DA10E Q39091854-005C38FC-A8F5-460A-A58A-EFF0ED08296B Q39236800-A17753B3-4C39-494E-A84F-629CFCA7F466 Q39244558-80E96D43-CB85-4710-B4AC-4438699D8B5C Q39790276-48A96FBA-D984-4407-A279-4A2FF5AA3230 Q40088616-CC904989-AB4C-489F-BBD0-F4CE18EFB698 Q40405913-3B3D7FCB-DDCD-4867-9BB8-B472F8C64AC6 Q40405921-79A4AA2B-F43A-4A28-9D90-35B08E24C238 Q40750820-B767D51A-81C0-420E-ADBA-37E117BBC3A1 Q41919495-49265DDA-04A7-44EB-87F2-63A5D70CD0FA Q42352666-EFF25464-676E-486C-A12E-F6925EAB0422 Q46250879-804F3494-4357-4B36-B6D7-D36275029037 Q47142027-19072F95-549A-49B5-BE21-63E4794C6E4B Q47607348-1CDA00E2-E1C3-4ECC-BD9D-01B6CB8DC08B Q47629630-58188C51-004A-47BA-8AD2-797BFBD3FB2C Q47736893-098D5DA1-A2EC-4200-BEE2-A92C5039DA23 Q49715007-95869B09-62F3-4712-9FB6-561D6533FDAD Q52589409-29AF5DB8-6442-47D0-ADC8-3E4BD5413D12 Q52609655-4823A12C-EB97-4795-91E5-F498998BBF9B Q52720366-13E66A38-F268-4C36-B281-4D7CB9A2293F Q52868672-FA8431FC-EE2D-4449-8567-89CE3491FA81 Q54217790-41E7DF97-CFD8-4FB6-8D13-052E3082CCB8 Q55023090-8E9283D9-F27E-4F7A-96F8-7C160AD49C32 Q55135924-04F0745A-988E-4BE2-B848-58D478664094 Q56057560-3DEFA80B-3D85-4ED6-AA1A-9615CEB198F4 Q57072744-62A83090-E170-4644-A9CD-4A1437289950 Q58721961-B35B5C3B-CB09-49E2-92C1-06C43654BEB5

P2860

Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals.

http://www.wikidata.org/entity/Q36757051

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Sequence-engineered mRNA Witho ...... tein Therapy in Large Animals.

@ast

Sequence-engineered mRNA Witho ...... tein Therapy in Large Animals.

@en

type

label

Sequence-engineered mRNA Witho ...... tein Therapy in Large Animals.

@ast

Sequence-engineered mRNA Witho ...... tein Therapy in Large Animals.

@en

prefLabel

Sequence-engineered mRNA Witho ...... tein Therapy in Large Animals.

@ast

Sequence-engineered mRNA Witho ...... tein Therapy in Large Animals.

@en

P1433

Q36757051-66CFFA42-D5F2-4F99-91BC-6CB960F87B3A

P1476

Q36757051-445DBD94-503C-4F3A-AFB9-D987FDB505D6

P2093

Q36757051-68542DEB-6CC3-4378-85A4-D428B4FE3063

Q36757051-7B1DE58A-4159-4590-B283-C19C03152621

Q36757051-7D38DE29-BEA0-47BE-9EF0-B0191991D61A

Q36757051-AD7321CF-FEEB-4AB3-988A-183C13725085

Q36757051-DE1F060A-0ABC-4F89-826F-31A4E1E5402F

Q36757051-E74D1887-4B9D-40C0-93EE-782E030861F9

Q36757051-EABA8225-CF43-45D6-955D-91235F1D2AC3

P2860

Q36757051-03381E2B-295D-433D-9EDD-A9B9D1BED5A8

Q36757051-05A82F54-BA7C-4C36-B253-4D6DF450BC88

Q36757051-0878F3CD-302F-429B-BD43-2979E653C465

Q36757051-11279AE0-3DE9-49B1-A7F8-DDD535F41EB1

Q36757051-21E7436F-BEDD-4239-9FFA-A6B79D28E055

Q36757051-3F10BB79-646D-4F5F-B6D5-40CECE558B75

Q36757051-405A20FC-4735-429E-8D8F-A772EF001749

Q36757051-43642EBC-91FB-4A83-96D7-CD63EF87C0BD

Q36757051-457788B7-986B-406B-B1EF-AB44B735393F

Q36757051-46D19BC1-7A80-43E5-8D29-91916DB22AFA

P304

Q36757051-C7D455E7-CB3D-4FDD-B75B-3E392B12E699

P31

Q36757051-ADD39E87-7FEE-4E86-A74E-726000F3E9D8

P356

Q36757051-3F2A9012-0A20-4C98-809E-59061B5C119C

P433

Q36757051-6A4FC34E-4455-435B-90E7-0D5ABC3DCBE0

P478

Q36757051-6227D468-81C9-43A0-8F0F-3E97E6399640

P577

Q36757051-927E9983-963B-40E5-A4B6-5B16C3269853

P698

Q36757051-D132A0B9-14DC-4F05-8C71-47857744F2BE

P932

Q36757051-61241BA5-34DC-422E-872F-BB9814738CAA

P356

P1433

Molecular Therapy

P1476

Sequence-engineered mRNA Witho ...... tein Therapy in Large Animals.

@en

P2093

Andreas Thess

http://www.w3.org/2001/XMLSchema#string

Barbara L Mui

http://www.w3.org/2001/XMLSchema#string

Mariola Fotin-Mleczek

http://www.w3.org/2001/XMLSchema#string

Michael J Hope

http://www.w3.org/2001/XMLSchema#string

Patrick Baumhof

http://www.w3.org/2001/XMLSchema#string

Stefanie Grund

http://www.w3.org/2001/XMLSchema#string

Thomas Schlake

http://www.w3.org/2001/XMLSchema#string

P2860

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA

Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates

Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA.

5'-Triphosphate RNA is the ligand for RIG-I

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.

Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction

P304

1456-1464

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2015.103

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26050989

http://www.w3.org/2001/XMLSchema#string

P932

4817881

http://www.w3.org/2001/XMLSchema#string